<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932110</url>
  </required_header>
  <id_info>
    <org_study_id>DDagdelen</org_study_id>
    <nct_id>NCT03932110</nct_id>
  </id_info>
  <brief_title>Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels</brief_title>
  <official_title>The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis
      patients as well as the parameters of metabolic syndrome will be examined. At the same time,
      the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity
      will be measured by measuring the disease severity (by PASI psoriasis, clinical activity
      score for psoriatic arthritis). The patients who accepted to participate in the study , who
      were admitted to the dermatology outpatient clinic were included in the study. For the blood
      tests required after the examination, 2 tubes of blood will be taken for the measurement of
      omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were
      planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the
      diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with
      the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined
      whether it is proinflammatory or antiinflammatory.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>omentin</measure>
    <time_frame>6 months</time_frame>
    <description>Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>visfatin</measure>
    <time_frame>6 months</time_frame>
    <description>Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>psoriasis vulgaris,</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients who have only psoriasis vulgaris</description>
  </arm_group>
  <arm_group>
    <arm_group_label>psoriatic arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients who have psoriatic arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>healthy people</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>omentin, visfatin</intervention_name>
    <description>diagnostic blood test</description>
    <arm_group_label>healthy control</arm_group_label>
    <arm_group_label>psoriasis vulgaris,</arm_group_label>
    <arm_group_label>psoriatic arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and
             rheumatology clinic

          2. Patients older than 18 years

          3. Patients who accept dermatological and rheumatic examination

          4. Patients not receiving systemic treatment related to the disease in the last 1 month

        Exclusion Criteria:

          1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic
             arthritis

          2. Patients under 18 years

          3. Patients who do not accept dermatological and rheumatic examination Patients receiving
             systemic therapy for the last 1 month pregnant and nursing moms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul Medeniyet University, Department of dermatology</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Medeniyet University</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Deniz DaÄŸdelen</investigator_full_name>
    <investigator_title>M. D.</investigator_title>
  </responsible_party>
  <keyword>psoriasis vulgaris</keyword>
  <keyword>psoriatic arthritis</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>omentin</keyword>
  <keyword>visfatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

